AG真人官方

XCF Global, Inc. (NASDAQ: SAFX) filed an 8-K disclosing two related amendments executed on July 10 2025:

• Amendment No. 1 to a Promissory Note (originally dated May 30 2025) among Focus Impact BH3 NewCo, Inc. (borrower), Helena Global Investment Opportunities I Ltd ("Helena") and Randall Soule. In exchange for a $2,249,771.14 cash payment from Helena, the Company and Soule waived Helena鈥檚 obligation to return certain Class A common shares that had been subject to Section 11.2 of the original note.
• Soule Amendment to Share Issuance Agreement (dated May 30 2025) under which Soule will return unspecified Class A shares to the Company for cancellation.

Because Amendment No. 1 alters the payment terms, the disclosure is also reported under Item 2.03 (creation of a direct financial obligation). Forms of both amendments are attached as Exhibits 10.1 and 10.2.

Key take-aways for investors:

• The Company receives $2.25 million in cash, enhancing near-term liquidity.
• The waiver means Helena retains shares that would otherwise have been returned, potentially maintaining share count higher than previously expected.
• Soule鈥檚 return of shares partly offsets the dilution, but the precise number of shares affected is not disclosed in the filing.

Marvell Technology, Inc. (MRVL) has filed a Form 144 indicating that insider Panteha Dixon intends to sell 1,273 common shares through Morgan Stanley Smith Barney on or about 15 July 2025. The shares have an aggregate market value of $93,794.64, representing roughly 0.00015% of the company鈥檚 862.2 million shares outstanding鈥攁n immaterial fraction at the corporate level. The filing also discloses that Dixon sold 3,808 shares over the prior three months for total proceeds of roughly $252 thousand. No Rule 10b5-1 trading plan adoption date is listed, and the filer affirms no knowledge of undisclosed material information. Overall, this appears to be routine, small-scale insider profit-taking rather than a transaction likely to influence Marvell鈥檚 fundamental outlook.

Copart Inc. (CPRT) has filed a Form 144 indicating the proposed sale of 24,088 common shares through Morgan Stanley Smith Barney on the NASDAQ around 15 July 2025. The shares were recently acquired on the same date via the cash exercise of stock options. Based on the filing鈥檚 stated outstanding share count of 966.9 million, the planned sale represents roughly 0.0025 % of total shares, with an aggregate market value of $1.14 million. No other sales by the same insider were reported in the past three months, and no additional material information鈥攕uch as the seller鈥檚 identity or relationship to the issuer鈥攚as disclosed.

The notice is routine and does not, by itself, suggest any change in Copart鈥檚 fundamentals; rather, it provides procedural advance disclosure required when an insider intends to sell restricted or control securities under Rule 144.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) filed a Form 8-K dated July 14, 2025 reporting two material events.

• Item 2.02 鈥� Results of Operations and Financial Condition: The Company released a preliminary estimate of its cash, cash equivalents and short-term investments as of June 30, 2025. No dollar amount was disclosed and management cautions that the figure is subject to change when full second-quarter results are issued.
• Item 8.01 鈥� Other Events: A press release titled 鈥淎tara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel庐)鈥� was furnished as Exhibit 99.1 and incorporated by reference. Specific regulatory or business details are not included in the 8-K text.

The filing contains no detailed financial statements, earnings figures, or transactional information. Investors will need to review the forthcoming Form 10-Q and Exhibit 99.1 for quantitative data and substantive regulatory updates.

Incyte Corporation (INCY) 鈥� Form 4 insider filing

Executive Vice President of Human Resources Paula J. Swain reported a Code F transaction dated 07/02/2025. The company automatically withheld 6,285 common shares at a fair-market price of $68.17 to satisfy tax obligations triggered by the vesting of previously granted restricted and performance stock units. After this non-open-market withholding, Swain鈥檚 direct beneficial ownership totals 101,059 common shares, including 34,329 unvested RSUs/PSUs.

The filing represents routine administrative tax settlement; no discretionary purchase or sale of shares occurred.

Form 4 filing overview: On 07/02/2025, Incyte Corp. (INCY) Principal Accounting Officer Tray Thomas satisfied tax-withholding obligations related to previously granted restricted stock units (RSUs).

• Transaction code F denotes shares withheld by the issuer for taxes鈥攏ot an open-market sale.
• Shares withheld: 897 common shares at an implied price of $68.17.
• Post-transaction holdings: 21,106 common shares, of which 13,456 are unvested RSUs.

No derivative securities were exercised or disposed of. The filing represents an administrative, non-discretionary transaction and does not signal a change in the executive鈥檚 investment thesis or company fundamentals.

Form 4 filing overview 鈥� Incyte Corp. (INCY)

Executive Vice President & Chief Medical Officer Dr. Steven H. Stein reported an internal share withholding transaction dated 07/02/2025. The Code 鈥淔鈥� event reflects 12,714 common shares automatically withheld by the issuer to cover tax obligations arising from the settlement of previously granted restricted stock units (RSUs) or earned performance shares. The withholding price was $68.17 per share.

After the transaction, Dr. Stein directly owns 112,418 common shares. This figure includes 94,907 unvested RSUs/performance shares that remain subject to future vesting conditions. No open-market purchases or sales and no derivative security activity were reported.

The filing represents a routine administrative tax-related disposition and does not signal a discretionary sale. There are no indications of broader strategic changes, earnings data, or material corporate developments within this document.